- Condition: Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Intervention: Drug: Ruxolitinib
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Not yet recruiting - verified May 2012 - Conditions: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel; Drug: Paclitaxel
Sponsors: German Breast Group; German Breast Group; Celgene GmbH; Roche Pharma AG
Not yet recruiting - verified April 2012 - Condition: Breast Cancer Invasive Nos
Intervention:
Sponsors: Spanish Breast Cancer Research Group; Spanish Breast Cancer Research Group; Hoffmann-La Roche; Roche Farma, S.A
Not yet recruiting - verified May 2012 - Conditions: Breast Cancer; Breast Cancer Stage II-III
Intervention: Drug: Docetaxel- Carboplatin
Sponsors: Hospital General Universitario Gregorio Marañon; Hospital General Universitario Gregorio Marañon; UNC Lineberger Comprehensive Cancer Center; Hospital Universitario Ramon y Cajal; Hospital San Carlos, Madrid; Centro Nacional de Investigaciones Oncologicas CARLOS III
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Breast Neoplasms
Interventions: Drug: lapatinib ditosylate; Biological: trastuzumab
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Circulating Tumor Cells
Intervention: Drug: trastuzumab
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; Hoffmann-La Roche
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Radiation: External Beam Partial-Breast Irradiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital
Recruiting - verified May 2012 - Conditions: in Situ Breast Cancer; Invasive Breast Cancer
Interventions: Procedure: Insertion of suction drain(s) following mastectomy; Procedure: Adaptive skin sutures.
Sponsors: National Institute of Oncology, Hungary; National Institute of Oncology, Hungary
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Behavioral: Exercise Program; Behavioral: Telephone Counseling Calls; Behavioral: Standard Care; Behavioral: Health Behavior Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Invasive Adenocarcinoma of the Breast
Interventions: Procedure: Cryoablation; Biological: Ipilimumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: Pazopanib plus capecitabine
Sponsors: German Breast Group; German Breast Group
Active, not recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Procedure: Lumpectomy, axillary block dissection, breast conserving surgery; Other: Radiotherapy
Sponsors: National Institute of Oncology, Hungary; National Institute of Oncology, Hungary
Recruiting - verified December 2011 - Condition: Primary Invasive Breast Cancer
Intervention:
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: letrozole; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: breast imaging study; Procedure: dynamic contrast-enhanced magnetic resonance imaging; Procedure: neoadjuvant therapy; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer
Interventions: Drug: Carboplatin; Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
Sponsors: German Breast Group; German Breast Group; Cephalon; Roche Pharma AG; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer
Interventions: Drug: zoledronic acid; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Inflammatory Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Mucinous Ductal Breast Carcinoma; Papillary Ductal Breast Carcinoma; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Tubular Ductal Breast Carcinoma
Intervention: Radiation: External beam radiation therapy
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Breast Cancer
Intervention: Radiation: Accelerated partial breast irradiation
Sponsors: Brown University; Jaroslaw Hepel; The Miriam Hospital; Rhode Island Hospital
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Radiation: IMRT with an simultaneous integrated boost
Sponsors: Fudan University; Fudan University
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Device: Visica 2™ Treatment System; Procedure: Cryoablation; Procedure: Surgical Resection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Conditions: Breast Image Scale Index for Self Esteem Evaluation; Breast Symmetry Index; Quality of Life; Morbidity; Oncological Outcome
Interventions: Procedure: Breast Surgery; Procedure: Breast Surgery
Sponsors: Medical University of Vienna; Medical University of Vienna
Recruiting - verified April 2011 - Condition: Ductal Carcinoma in Situ
Intervention: Drug: SOM 230 / Pasireotide
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified April 2012 - Condition: Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified January 2012
 |
Join Clinical Trials in Amarillo Texas |
